News | May 26, 2025
Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
EBITDA before special items decreases to €4.08 billion (7.4%)
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Bayer expects 2025 to be the most difficult year of its turnaround
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
Subscribe To Our Newsletter & Stay Updated
